MARKET

ENGN

ENGN

enGene Holdings Inc.
NASDAQ
9.53
-0.21
-2.16%
After Hours: 9.64 +0.11 +1.15% 16:42 02/10 EST
OPEN
9.71
PREV CLOSE
9.74
HIGH
10.12
LOW
9.50
VOLUME
230.34K
TURNOVER
--
52 WEEK HIGH
12.25
52 WEEK LOW
2.650
MARKET CAP
638.36M
P/E (TTM)
-4.1530
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (0202-0206)?
Weekly Report · 1d ago
enGene to Spotlight Bladder Cancer Gene Therapy at Guggenheim Biotech Summit 2026
TipRanks · 6d ago
enGene CEO to Highlight Genetic Medicine Strategy at Guggenheim Biotech Summit 2026
TipRanks · 6d ago
enGene Holdings nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 6d ago
enGene Holdings CEO to Join Guggenheim Emerging Outlook Biotech Summit
Reuters · 6d ago
Weekly Report: what happened at ENGN last week (0126-0130)?
Weekly Report · 02/02 09:10
Spotify upgraded, Pinterest downgraded: Wall Street’s top analyst calls
TipRanks · 01/30 14:56
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
TipRanks · 01/30 13:23
More
About ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.